Pliant Therapeutics (PLRX) Shares Outstanding (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Shares Outstanding (Entity) of $61.9 million for Q1 2026, up 0.86% year-over-year from $61.4 million in Q1 2025, and up 0.76% quarter-over-quarter from $61.4 million in Q4 2025.
Pliant Therapeutics (PLRX) Shares Outstanding (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $61.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 0.86% year-over-year to $61.9 million; the TTM figure through Mar 2026 stood at $61.9 million (up 0.86% YoY), while the FY2025 annual figure was $61.4 million, up 0.97% from the prior year.
- Shares Outstanding (Entity) climbed to $61.9 million in Q1 2026 per PLRX's latest filing, from $61.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $61.9 million in Q1 2026 and bottomed at $36.2 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $56.4 million across 5 years, with a median of $60.3 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) jumped 63.68% — and 2026, when it gained 0.86%.
- Pliant Therapeutics' Shares Outstanding (Entity) stood at $48.9 million in 2022, then increased by 22.43% to $59.9 million in 2023, then increased by 1.57% to $60.9 million in 2024, then increased by 0.97% to $61.4 million in 2025, then increased by 0.76% to $61.9 million in 2026.
- Business Quant data shows PLRX's Shares Outstanding (Entity) at $61.9 million in Q1 2026, $61.4 million in Q4 2025, and $61.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 61.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.92 Mn |
| Mar 31, 2026 | 61.80 Mn |
| Dec 31, 2025 | 61.37 Mn |
| Sep 30, 2025 | 61.41 Mn |
| Jun 30, 2025 | 61.39 Mn |
| Mar 31, 2025 | 61.22 Mn |
| Dec 31, 2024 | 60.54 Mn |
| Sep 30, 2024 | 60.73 Mn |
| Jun 30, 2024 | 60.38 Mn |
| Mar 31, 2024 | 60.18 Mn |
| Dec 31, 2023 | 58.72 Mn |
| Sep 30, 2023 | 59.69 Mn |
| Jun 30, 2023 | 59.17 Mn |
| Mar 31, 2023 | 56.06 Mn |
| Dec 31, 2022 | 42.02 Mn |
| Sep 30, 2022 | 46.80 Mn |
| Jun 30, 2022 | 36.17 Mn |
| Mar 31, 2022 | 36.12 Mn |
| Dec 31, 2021 | 35.85 Mn |
| Sep 30, 2021 | 35.91 Mn |